| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Lushang Freda Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥8.44 |
| 52 Week High | CN¥11.63 |
| 52 Week Low | CN¥6.38 |
| Beta | 1.89 |
| 1 Month Change | 8.76% |
| 3 Month Change | 6.16% |
| 1 Year Change | -26.48% |
| 3 Year Change | -51.49% |
| 5 Year Change | n/a |
| Change since IPO | 10.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| 600223 | CN Real Estate | CN Market | |
|---|---|---|---|
| 7D | -4.0% | 5.9% | -0.5% |
| 1Y | -26.5% | -21.7% | -11.3% |
Return vs Industry: 600223 underperformed the CN Real Estate industry which returned -21.7% over the past year.
Return vs Market: 600223 underperformed the CN Market which returned -11.3% over the past year.
Price Volatility
| 600223 volatility | |
|---|---|
| 600223 Average Weekly Movement | 5.9% |
| Real Estate Industry Average Movement | 6.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in CN Market | 10.8% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 600223 has not had significant price volatility in the past 3 months.
Volatility Over Time: 600223's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 3,651 | n/a | www.lshzy.com.cn |
Lushang Freda Pharmaceutical Co.,Ltd. develops and operates real estate properties in China. The company offers property management services, such as non-owner value-added and community value-added services.
Lushang Freda Pharmaceutical Co.,Ltd. Fundamentals Summary
| 600223 fundamental statistics | |
|---|---|
| Market cap | CN¥8.58b |
| Earnings (TTM) | CN¥233.09m |
| Revenue (TTM) | CN¥4.20b |
36.8x
P/E Ratio2.0x
P/S RatioIs 600223 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600223 income statement (TTM) | |
|---|---|
| Revenue | CN¥4.20b |
| Cost of Revenue | CN¥2.12b |
| Gross Profit | CN¥2.07b |
| Other Expenses | CN¥1.84b |
| Earnings | CN¥233.09m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.23 |
| Gross Margin | 49.39% |
| Net Profit Margin | 5.55% |
| Debt/Equity Ratio | 13.7% |
How did 600223 perform over the long term?
See historical performance and comparison